<p>X4 Pharmaceuticals（纳斯达克代码：XFOR - 获取免费报告）在周三发布给投资者的报告中，被 Zacks Research 的股票研究人员从 “强力买入” 评级下调至 “持有” 评级，Zacks.com 报道。</p>
<p>其他一些研究公司也对 XFOR 发表了评论。Stifel Nicolaus 在 11 月 5 日的研究报告中对 X4 Pharmaceuticals 设定了 7.50 美元的目标价。华尔街 Zen 在 11 月 22 日的研究报告中将 X4 Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。HC Wainwright 在 8 月 13 日的研究报告中对 X4 Pharmaceuticals 的股票设定了 3.50 美元的目标价，并给予该公司 “买入” 评级。最后，Weiss Ratings 在周一的报告中重新发布了对 X4 Pharmaceuticals 的 “卖出（d-）” 评级。三位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价为 33.67 美元。</p>
<p>获取 <strong>X4 Pharmaceuticals</strong> 的提醒：</p>
<p><strong>查看我们关于 X4 Pharmaceuticals 的最新研究报告</strong></p>
<h2>X4 Pharmaceuticals 股价上涨 1.1%</h2>
<p>XFOR 的股票在周三以 3.68 美元开盘。该公司的流动比率为 5.65，速动比率为 5.48，债务与股本比率为 1.23。该股票的市值为 3.2178 亿美元，市盈率为-0.36，贝塔值为 0.51。X4 Pharmaceuticals 的 1 年最低价为 1.35 美元，1 年最高价为 26.83 美元。该股票的 50 日简单移动平均价为 3.52 美元，200 日简单移动平均价为 2.98 美元。</p>
<p>X4 Pharmaceuticals（纳斯达克代码：XFOR - 获取免费报告）最后一次公布财报是在 11 月 5 日。该公司报告的每股收益（EPS）为（0.69 美元），超出分析师的共识预期（0.79 美元）0.10 美元。该业务在该季度的收入为 177 万美元，而分析师的预期为 205 万美元。X4 Pharmaceuticals 的净利润率为-279.86%，股本回报率为-343.67%。平均而言，卖方分析师预测 X4 Pharmaceuticals 在当前财年将发布-0.68 的每股收益。</p>
<h2>内部活动</h2>
<p>在相关消息中，董事长 Adam R. Craig 在 10 月 23 日的交易中购买了 86,206 股该公司的股票。股票的平均购买成本为每股 2.90 美元，总价值为 249,997.40 美元。购买完成后，董事长直接持有该公司 376,087 股股票，价值约为 1,090,652.30 美元。这笔交易代表了他们持股比例的 29.74% 的增长。该购买在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上查阅。2.37% 的股票由公司内部人士持有。</p>
<h2>对 X4 Pharmaceuticals 的对冲基金看法</h2>
<p>几家机构投资者最近调整了对该公司的持股。查尔斯·施瓦布投资管理公司在第一季度将其在 X4 Pharmaceuticals 的持股增加了 9.9%。查尔斯·施瓦布投资管理公司目前拥有 481,528 股该公司的股票，价值 114,000 美元，此前在上个季度又购买了 43,320 股。Pale Fire Capital SE 在第一季度将其在 X4 Pharmaceuticals 的持股增加了 45.2%。Pale Fire Capital SE 目前拥有 2,035,362 股该公司的股票，价值 481,000 美元，此前在上个季度又购买了 633,398 股。Kingdon Capital Management L.L.C.在第一季度将其在 X4 Pharmaceuticals 的持股增加了 41.8%。Kingdon Capital Management L.L.C.目前拥有 7,000,000 股该公司的股票，价值 1,655,000 美元，此前在上个季度又购买了 2,063,000 股。Acorn Capital Advisors LLC 在第三季度将其在 X4 Pharmaceuticals 的持股增加了 77.8%。Acorn Capital Advisors LLC 目前拥有 273,349 股该公司的股票，价值 935,000 美元，此前在上个季度又购买了 119,619 股。最后，Boothbay Fund Management LLC 在第三季度购买了 X4 Pharmaceuticals 的新头寸，价值 1,176,000 美元。机构投资者持有该公司 72.03% 的股票。</p>
<h2>X4 Pharmaceuticals 公司简介</h2>
<p>（获取免费报告）</p>
<p>X4 Pharmaceuticals, Inc 是一家处于后期临床阶段的生物制药公司，专注于稀有疾病的创新治疗药物的研究、开发和商业化。其主要产品候选药物是 mavorixafor，一种小分子化合物，抑制趋化因子受体 C-X-C 趋化因子受体 4（CXCR4），目前正在进行针对疣、低丙种球蛋白血症、感染和骨髓滞留综合症的 III 期临床试验；以及针对先天性、特发性或周期性中性粒细胞减少症的 II 期临床试验。</p>
<h2>推荐阅读</h2>
<ul>
<li>我们更看好的五只股票超过 X4 Pharmaceuticals</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>MarketBeat 周回顾 – 11/24 - 11/28</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>持续发力：Applied Digital 的首个 AI 数据中心上线</li>
<li>股票拆分意味着什么？</li>
<li>Alphabet：最有可能主导 2026 年的 AI 领导者</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEZPUg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEZPUg"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 X4 Pharmaceuticals 吗？</h2>
<p>在你考虑 X4 Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 X4 Pharmaceuticals 并不在名单上。</p>
<p>虽然 X4 Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

XFOR

<p>Zacks Research 将 X4 Pharmaceuticals（NASDAQ:XFOR）的评级从 “强力买入” 下调至 “持有”。其他分析师的评级各不相同，平均评级为 “持有”，共识目标价为 33.67 美元。该股票周三开盘价为 3.68 美元。X4 Pharmaceuticals 报告第三季度每股收益为（0.69 美元），超出预期 0.10 美元。机构投资者持有该股票 72.03%</p>

<p>X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) was downgraded by equities researchers at Zacks Research from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a note issued to investors on Wednesday,Zacks.com reports.</p>
<div class="lb-trans"><p>X4 Pharmaceuticals（纳斯达克代码：XFOR - 获取免费报告）在周三发布给投资者的报告中，被 Zacks Research 的股票研究人员从 “强力买入” 评级下调至 “持有” 评级，Zacks.com 报道。</p>
</div><p>A number of other research firms have also commented on XFOR. Stifel Nicolaus set a $7.50 price objective on X4 Pharmaceuticals in a research note on Wednesday, November 5th. Wall Street Zen upgraded shares of X4 Pharmaceuticals from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Saturday, November 22nd. HC Wainwright set a $3.50 price target on shares of X4 Pharmaceuticals and gave the company a &#34;buy&#34; rating in a research note on Wednesday, August 13th. Finally, Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of X4 Pharmaceuticals in a report on Monday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of &#34;Hold&#34; and a consensus price target of $33.67.</p>
<div class="lb-trans"><p>其他一些研究公司也对 XFOR 发表了评论。Stifel Nicolaus 在 11 月 5 日的研究报告中对 X4 Pharmaceuticals 设定了 7.50 美元的目标价。华尔街 Zen 在 11 月 22 日的研究报告中将 X4 Pharmaceuticals 的股票评级从 “卖出” 上调至 “持有”。HC Wainwright 在 8 月 13 日的研究报告中对 X4 Pharmaceuticals 的股票设定了 3.50 美元的目标价，并给予该公司 “买入” 评级。最后，Weiss Ratings 在周一的报告中重新发布了对 X4 Pharmaceuticals 的 “卖出（d-）” 评级。三位分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该公司的平均评级为 “持有”，共识目标价为 33.67 美元。</p>
</div><p>Get <strong>X4 Pharmaceuticals</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>X4 Pharmaceuticals</strong> 的提醒：</p>
</div><p><strong>Check Out Our Latest Research Report on X4 Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 X4 Pharmaceuticals 的最新研究报告</strong></p>
</div><h2>X4 Pharmaceuticals Trading Up 1.1%</h2>
<div class="lb-trans"><h2>X4 Pharmaceuticals 股价上涨 1.1%</h2>
</div><p>Shares of XFOR opened at $3.68 on Wednesday. The company has a current ratio of 5.65, a quick ratio of 5.48 and a debt-to-equity ratio of 1.23. The stock has a market cap of $321.78 million, a PE ratio of -0.36 and a beta of 0.51. X4 Pharmaceuticals has a 1 year low of $1.35 and a 1 year high of $26.83. The stock has a 50 day simple moving average of $3.52 and a 200-day simple moving average of $2.98.</p>
<div class="lb-trans"><p>XFOR 的股票在周三以 3.68 美元开盘。该公司的流动比率为 5.65，速动比率为 5.48，债务与股本比率为 1.23。该股票的市值为 3.2178 亿美元，市盈率为-0.36，贝塔值为 0.51。X4 Pharmaceuticals 的 1 年最低价为 1.35 美元，1 年最高价为 26.83 美元。该股票的 50 日简单移动平均价为 3.52 美元，200 日简单移动平均价为 2.98 美元。</p>
</div><p>X4 Pharmaceuticals (NASDAQ:XFOR - Get Free Report) last announced its earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.79) by $0.10. The business had revenue of $1.77 million during the quarter, compared to analysts' expectations of $2.05 million. X4 Pharmaceuticals had a negative net margin of 279.86% and a negative return on equity of 343.67%. On average, sell-side analysts predict that X4 Pharmaceuticals will post -0.68 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>X4 Pharmaceuticals（纳斯达克代码：XFOR - 获取免费报告）最后一次公布财报是在 11 月 5 日。该公司报告的每股收益（EPS）为（0.69 美元），超出分析师的共识预期（0.79 美元）0.10 美元。该业务在该季度的收入为 177 万美元，而分析师的预期为 205 万美元。X4 Pharmaceuticals 的净利润率为-279.86%，股本回报率为-343.67%。平均而言，卖方分析师预测 X4 Pharmaceuticals 在当前财年将发布-0.68 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, Chairman Adam R. Craig acquired 86,206 shares of the firm's stock in a transaction that occurred on Thursday, October 23rd. The stock was acquired at an average cost of $2.90 per share, with a total value of $249,997.40. Following the completion of the purchase, the chairman directly owned 376,087 shares in the company, valued at approximately $1,090,652.30. This trade represents a 29.74% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. 2.37% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在相关消息中，董事长 Adam R. Craig 在 10 月 23 日的交易中购买了 86,206 股该公司的股票。股票的平均购买成本为每股 2.90 美元，总价值为 249,997.40 美元。购买完成后，董事长直接持有该公司 376,087 股股票，价值约为 1,090,652.30 美元。这笔交易代表了他们持股比例的 29.74% 的增长。该购买在向证券交易委员会的备案中披露，相关信息可在 SEC 网站上查阅。2.37% 的股票由公司内部人士持有。</p>
</div><h2>Hedge Funds Weigh In On X4 Pharmaceuticals</h2>
<div class="lb-trans"><h2>对 X4 Pharmaceuticals 的对冲基金看法</h2>
</div><p>Several institutional investors have recently modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in X4 Pharmaceuticals by 9.9% during the first quarter. Charles Schwab Investment Management Inc. now owns 481,528 shares of the company's stock worth $114,000 after acquiring an additional 43,320 shares in the last quarter. Pale Fire Capital SE raised its stake in shares of X4 Pharmaceuticals by 45.2% during the 1st quarter. Pale Fire Capital SE now owns 2,035,362 shares of the company's stock worth $481,000 after purchasing an additional 633,398 shares in the last quarter. Kingdon Capital Management L.L.C. boosted its holdings in shares of X4 Pharmaceuticals by 41.8% in the 1st quarter. Kingdon Capital Management L.L.C. now owns 7,000,000 shares of the company's stock valued at $1,655,000 after buying an additional 2,063,000 shares during the last quarter. Acorn Capital Advisors LLC boosted its holdings in shares of X4 Pharmaceuticals by 77.8% in the 3rd quarter. Acorn Capital Advisors LLC now owns 273,349 shares of the company's stock valued at $935,000 after buying an additional 119,619 shares during the last quarter. Finally, Boothbay Fund Management LLC bought a new position in shares of X4 Pharmaceuticals in the third quarter valued at $1,176,000. Institutional investors own 72.03% of the company's stock.</p>
<div class="lb-trans"><p>几家机构投资者最近调整了对该公司的持股。查尔斯·施瓦布投资管理公司在第一季度将其在 X4 Pharmaceuticals 的持股增加了 9.9%。查尔斯·施瓦布投资管理公司目前拥有 481,528 股该公司的股票，价值 114,000 美元，此前在上个季度又购买了 43,320 股。Pale Fire Capital SE 在第一季度将其在 X4 Pharmaceuticals 的持股增加了 45.2%。Pale Fire Capital SE 目前拥有 2,035,362 股该公司的股票，价值 481,000 美元，此前在上个季度又购买了 633,398 股。Kingdon Capital Management L.L.C.在第一季度将其在 X4 Pharmaceuticals 的持股增加了 41.8%。Kingdon Capital Management L.L.C.目前拥有 7,000,000 股该公司的股票，价值 1,655,000 美元，此前在上个季度又购买了 2,063,000 股。Acorn Capital Advisors LLC 在第三季度将其在 X4 Pharmaceuticals 的持股增加了 77.8%。Acorn Capital Advisors LLC 目前拥有 273,349 股该公司的股票，价值 935,000 美元，此前在上个季度又购买了 119,619 股。最后，Boothbay Fund Management LLC 在第三季度购买了 X4 Pharmaceuticals 的新头寸，价值 1,176,000 美元。机构投资者持有该公司 72.03% 的股票。</p>
</div><h2>X4 Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>X4 Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.</p>
<div class="lb-trans"><p>X4 Pharmaceuticals, Inc 是一家处于后期临床阶段的生物制药公司，专注于稀有疾病的创新治疗药物的研究、开发和商业化。其主要产品候选药物是 mavorixafor，一种小分子化合物，抑制趋化因子受体 C-X-C 趋化因子受体 4（CXCR4），目前正在进行针对疣、低丙种球蛋白血症、感染和骨髓滞留综合症的 III 期临床试验；以及针对先天性、特发性或周期性中性粒细胞减少症的 II 期临床试验。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐阅读</h2>
</div><ul>
<li>Five stocks we like better than X4 Pharmaceuticals</li>
<li>Unveiling The Power Of VWAP: A Key Indicator For Traders</li>
<li>MarketBeat Week in Review – 11/24 - 11/28</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>Power On: Applied Digital’s First AI Data Center Goes Live</li>
<li>What Does a Stock Split Mean?</li>
<li>Alphabet: The AI Leader Best Positioned to Dominate 2026</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 X4 Pharmaceuticals</li>
<li>揭示 VWAP 的力量：交易者的关键指标</li>
<li>MarketBeat 周回顾 – 11/24 - 11/28</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>持续发力：Applied Digital 的首个 AI 数据中心上线</li>
<li>股票拆分意味着什么？</li>
<li>Alphabet：最有可能主导 2026 年的 AI 领导者</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9WEZPUg" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=XFOR"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或评论发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in X4 Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 X4 Pharmaceuticals 吗？</h2>
</div><p>Before you consider X4 Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 X4 Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and X4 Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其向客户推荐的股票。MarketBeat 已经识别出五只顶级分析师悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而 X4 Pharmaceuticals 并不在名单上。</p>
</div><p>While X4 Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 X4 Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

X4 Pharmaceuticals（纳斯达克股票代码：XFOR）的股票评级被 Zacks Research 下调